CORBF vs. TALK, LFMD, CSTL, PSNL, FTRE, CELC, SBC, VMD, AIRS, and TOI
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Talkspace (TALK), LifeMD (LFMD), Castle Biosciences (CSTL), Personalis (PSNL), Fortrea (FTRE), Celcuity (CELC), SBC Medical Group (SBC), Viemed Healthcare (VMD), AirSculpt Technologies (AIRS), and Oncology Institute (TOI). These companies are all part of the "healthcare" industry.
Global Cord Blood vs.
Talkspace (NASDAQ:TALK) and Global Cord Blood (NYSE:CORBF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
Talkspace has a net margin of 0.61% compared to Global Cord Blood's net margin of 0.00%. Talkspace's return on equity of 0.98% beat Global Cord Blood's return on equity.
Talkspace received 6 more outperform votes than Global Cord Blood when rated by MarketBeat users.
In the previous week, Talkspace had 3 more articles in the media than Global Cord Blood. MarketBeat recorded 3 mentions for Talkspace and 0 mentions for Global Cord Blood. Talkspace's average media sentiment score of 1.49 beat Global Cord Blood's score of 0.00 indicating that Talkspace is being referred to more favorably in the media.
57.4% of Talkspace shares are held by institutional investors. 23.5% of Talkspace shares are held by insiders. Comparatively, 0.5% of Global Cord Blood shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Global Cord Blood has higher revenue and earnings than Talkspace.
Talkspace has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.68, suggesting that its share price is 168% less volatile than the S&P 500.
Talkspace presently has a consensus target price of $4.50, suggesting a potential upside of 63.04%. Given Talkspace's stronger consensus rating and higher possible upside, equities analysts plainly believe Talkspace is more favorable than Global Cord Blood.
Summary
Talkspace beats Global Cord Blood on 14 of the 16 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CORBF vs. The Competition
Global Cord Blood Competitors List
Related Companies and Tools
This page (NYSE:CORBF) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy CORBF Stock Free CORBF Stock Alerts